A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer. - A pilot study of low dose weekly docetaxel metronomic chemotherapy for previously treated advanced non-small cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007085

Enrollment

Registered

2012-01-23

Start date

2000-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

previously treated advanced non-small cell lung cancer

Interventions

15mg/m2 of docetaxel was administrated weekly.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologicaly or cytologicaly diagnosed previously treated NSCLC. Stage-IIIb or IV according to sixth edition of TNM classification at the enrollment. ECOG PS 0 or 1 (1) WBC>3,000/mm3 (2) neutrophil>1,500/mm3 (3) Hb>8.0 g/dL (4) platelet>100,000/mm3 (5) total bilirubine<1.5 mg/dL (6) AST(GOT)<70 IU/L (7) ALT(GPT)<70 IU/L (8) serum creatinine<1.5 mg/dL

Exclusion criteria

Exclusion criteria: 1) Patients with active double cancer. 2) Patients with infectious disease. 3) Patients with fever higher than 38 degree. 4) Female under pregnancy or lactation period.

Design outcomes

Primary

Measure	Time frame
Overall survival time Feasibility	—

Secondary

Measure	Time frame
Objective response rate	—

Countries

Japan

Contacts

Public ContactToshiki Shimizu

Kansai Medical University 1st department of internal medicine

shimizto@takii.kmu.ac.jp06-6992-1001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026